PBAC's latest decision on Ibandronic acid: Recommended with restriction (2008). Considered for Treatment of bone metastases from breast cancer. Oral formulation providing a more convenient dosing option compared to intravenous administration.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2006
Submissions
4
2006 → 2008
Eligible population
Patients with bone metastases from breast cancer, eligible for oral bisphosphonate therapy
Therapy area
Oncology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Surrogate
Key trials
MF4414, MF4434, MF4265, Body et al. 2007
Comparator
oral clodronate
Economic model
Cost-minimisation
Eligible patients/year
10,000
ICER note
Cost-minimisation analysis; no ICER calculated
Submission history
Jul 2006: Not recommended
Mar 2007: Recommended · Authority Required
Mar 2008: Not recommended
Nov 2008: Recommended with restriction · Restricted